Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioTech/Gish Introduces Downsized On-Pump Bypass System

This article was originally published in The Gray Sheet

Executive Summary

CardioTech's Gish Biomedical subsidiary will launch its anticoagulant-coated, "on-pump" cardiac bypass system in July following 510(k) clearance of the system's six components, announced June 18

You may also be interested in...



Off-Pump Cardiac Surgery More Cost-Effective Than On-Pump – NEJM

Future trials comparing beating- and stopped-heart cardiopulmonary bypass surgery should address patient risk profiles, mortality and complications, a study published in the Jan. 30 New England Journal of Medicine states

CardioTech/Gish

CardioTech will use Gish clean room facilities to manufacture polyurethane coronary artery bypass grafts after acquiring the Rancho Santa Margarita, California heart surgery products company for about $7.3 mil. in stock on Oct. 30. The deal also will increase CardioTech revenues by over 500%. CardioTech reported revenue of $3.2 mil. for the year ended March 31, while Gish had sales of $16 mil. in 2001...

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel